Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Perrigo Company plc (“Perrigo” or the “Company”) (NYSE: PRGO) investors concerning the Company and its officers’ possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
On December 21, 2018, Perrigo disclosed that it had received an audit finding letter from the Irish tax authorities stating “that IP sales transactions… including the sale of Tysabri®, were not part of the trade of Elan Pharma and therefore should have been treated as chargeable gains subject to an effective 33% tax rate, rather than the 12.5% tax rate applicable to trading income.” While the Company had disclosed on November 8, 2018 to investors that it had received the audit finding letter, it did not disclose further material details from the aforementioned letter.
On this news, Perrigo’s share price fell $15.33 per share, or more than 29%, to close at $37.03 per share on December 21, 2018, thereby injuring investors.
If you purchased Perrigo stock, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9244, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107006088/en/
Contacts:
Lesley Portnoy,
310-201-9150 or 888-773-9224
www.glancylaw.com
shareholders@glancylaw.com
